Description

1-(4-Acetylaminophenyl)-4-Methyl-7,8-Methylenedioxy-5H-2,3-Benzodiazepine is a high-purity, synthetically derived benzodiazepine derivative of significant interest in advanced pharmaceutical research and development. This compound serves as a critical chemical intermediate and a valuable pharmacological reference standard for studying neurological pathways and receptor interactions. It is primarily required by pharmaceutical R&D laboratories, contract research organizations (CROs), and academic institutions engaged in neuroscience and medicinal chemistry.

Application

• Pharmaceutical Intermediate: A key building block in the synthesis of novel therapeutic agents targeting the central nervous system.
• Reference Standard: Used for analytical method development, validation, and quality control in pharmaceutical manufacturing.
• Biochemical Research: Employed in in vitro studies to investigate ligand-receptor binding affinities and mechanisms of action.
• Medicinal Chemistry: Serves as a core scaffold for structure-activity relationship (SAR) studies to optimize potency and selectivity.
• Academic Research: Utilized in university and institutional labs for fundamental research in neuropharmacology and drug discovery.
• Pre-clinical Development: Acts as a candidate molecule or a metabolite analog in early-stage drug development pipelines.

Basic Information

Product Name	1-(4-Acetylaminophenyl)-4-Methyl-7,8-Methylenedioxy-5H-2,3-Benzodiazepine
CAS No.	177034-98-9
Molecular Formula	C19H17N3O3
Molecular Weight	335.36 g/mol
Synonyms	1-(4-Acetamidophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine; GYKI-52466; GYKI 52466; 4-Methyl-7,8-methylenedioxy-1-(4-acetylaminophenyl)-5H-2,3-benzodiazepine; 1-(4-Acetylaminophenyl)-4-methyl-7,8-(methylenedioxy)-5H-2,3-benzodiazepine; 5H-2,3-Benzodiazepine, 1-(4-(acetylamino)phenyl)-4-methyl-7,8-(methylenedioxy)-; Non-competitive AMPA receptor antagonist GYKI 52466
EINECS	Contact for details

Quality Control

Our 1-(4-Acetylaminophenyl)-4-Methyl-7,8-Methylenedioxy-5H-2,3-Benzodiazepine is manufactured under strict quality management systems. Each batch undergoes rigorous analytical testing, including HPLC for purity and NMR/IR for structural confirmation, to ensure it meets the high standards required for research applications. Certificates of Analysis (COA) detailing batch-specific results are provided and can be tailored to meet specific client or pharmacopeial requirements.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). The compound may be hygroscopic; therefore, containers should be kept tightly sealed in a dry environment to prevent moisture uptake.

Specification

Item	Specification
Appearance	White to off-white powder
Identification (IR)	Conforms to structure
Identification (HPLC)	Retention time matches reference standard
Purity (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0%
Water Content (KF)	≤ 0.5%
Residue on Ignition	≤ 0.1%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.